{
    "nct_id": "NCT04480502",
    "official_title": "ENVASARC: A Pivotal Trial Of Envafolimab, And Envafolimab In Combination With Ipilimumab, In Patients With Advanced Or Metastatic Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma Who Have Progressed On Prior Chemotherapy",
    "inclusion_criteria": "* Histologically confirmed locally advanced or metastatic undifferentiated pleomorphic sarcoma (UPS) or grade â‰¥ 2 myxofibrosarcoma (MFS)\n* Documented progression following systemic chemotherapy\n* At least one measurable lesion\n* Eastern Cooperative Oncology Group performance status of 0 or 1\n* Adequate hematologic and organ function\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "* More than two prior lines of chemotherapy for UPS/MFS\n* Prior immune checkpoint inhibitor or immunomodulatory therapy\n* Active autoimmune disease that has required systemic treatment\n* Major surgery within 4 weeks of dosing of investigational agent\n* Active additional malignancy\n* Pericardial effusion, pleural effusion, or ascites\n* Central nervous system metastases and/or carcinomatous meningitis\n* Active hepatitis or cirrhosis\n* Interstitial lung disease\n* Unwilling to apply highly effective contraception during the study\n* Other concurrent severe and/or uncontrolled medical conditions that would, in the investigator's judgment, contraindicate patient participation in the clinical study",
    "miscellaneous_criteria": ""
}